Home Analyst Price Target

Analyst Price Target

Scotts Miracle-Gro: Analysts’ Ratings after Q4

Scotts Miracle-Gro released its fiscal 2019 fourth-quarter and full-year results on November 6. Its stock has fallen 3.55% since its earnings release.

KushCo: 6 Analysts Say “Buy,” Price Target Shrinks

KushCo Holdings (KSHB) recently announced its fourth-quarter and full-year financial results. The company reported impressive results, beating analyst estimates. The company's stock is trading...

HEXO Corp: Analysts’ Ratings and Price Target

HEXO Corp (HEXO) is a Canada-based cannabis company. Recently, the company announced its fourth-quarter results for the period ending on July 31, 2019. The...

Tilray Struggles Post-Q3 as Most Analysts Say ‘Hold’

Like many of its peers, Tilray is struggling after its fiscal 2019 third-quarter release. Though its revenue met estimates, its stock continues to slide.

GW Pharmaceuticals: Analysts’ Ratings, Price Target

GW Pharmaceuticals (GWPH) recently reported its QA3 results. Although its financials beat estimates, the company's stock has fallen 18% since then.

Curaleaf: Analysts Are Hopeful ahead of Q3 Release

Curaleaf is set to report its third-quarter earnings results on November 19. It's fallen more than 6% since it announced its earnings date.

MedMen: Analysts’ Latest Ratings and Price Target

The cannabis sector is currently abuzz with earnings. MedMen Enterprises (MMEN) (MMNFF) is one of the first few to report.

Is Cronos Stock a Buy in October?

On October 28, Cronos (CRON) closed at 11.39 Canadian dollars on the Toronto Stock Exchange. This implies a 3.96% decline since the beginning of October.

Cronos Group: Analysts’ Target Prices and Ratings

Cronos Group (CRON) is already down by 15.59% so far in 2019. Although the company hasn’t escaped the gloom that has surrounded the cannabis...